Quest Diagnostics has had a number of noteworthy updates recently. The company has formed a biomarker partnership with
Octave Bioscience for multiple sclerosis, working with
Epic for a better laboratory testing experience. Their positive Q3 earnings report was accompanied by a raised outlook, attracting increased purchasing interest from
Norges Bank and multiple other investors. Meanwhile, the company has also completed an acquisition of clinical testing assets from
Fresenius Medical Care. Further good news includes a strong Q3 revenue growth and a dividend declaration, their stock is up by 2.6% since the last earnings report. Aside from surpassing expectations of consistent earnings growth, DGX has also broadened patient access via a strategic collaboration with Octave and launched testing for Oropouche Virus. Their well-performing stock is viewed as a strong value option for long-term growth. Despite concerns over Tariffs and Medicare Act Risks, the company remains ahead of Q3 earnings with strong expectations around their forthcoming report. Innovations via their Shield Partnership and a collaboration with Google Cloud using
Generative AI hint at a transformative role in preventive health and improved customer experiences.
Quest Diagnostics DGX News Analytics from Tue, 18 Mar 2025 07:00:00 GMT to Fri, 05 Dec 2025 11:55:00 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor -1
